Hereditary Apolipoprotein A-1 Amyloidosis With Glu34Lys Mutation Treated by Liver Transplantation: A Case Report.
Abdomen
/ diagnostic imaging
Amyloidosis, Familial
/ diagnosis
Apolipoprotein A-I
/ genetics
Humans
Liver
/ pathology
Liver Failure
/ surgery
Liver Transplantation
Living Donors
Magnetic Resonance Imaging
Male
Middle Aged
Polymorphism, Single Nucleotide
Spleen
/ pathology
Tomography, X-Ray Computed
Ultrasonography
Journal
Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
17
09
2020
accepted:
16
11
2020
pubmed:
13
2
2021
medline:
13
7
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Hereditary apolipoprotein A-1 (ApoA-1) amyloidosis is a rare disease characterized by progressive deposition of amyloid fibrils in the kidney, heart, and liver. We observed a 45-year-old male patient with liver failure. Liver dysfunction was detected at 30 years of age during an annual health check-up. At 35 years of age, renal dysfunction was also found. At 40 years of age, the pathologic findings of the liver revealed amyloid deposition. A testis biopsy specimen taken at 42 years of age to identify the cause of male infertility showed amyloid accumulation. At 43 years of age, the amyloid results and genetic profile led to a definitive diagnosis of hereditary ApoA-1 amyloidosis caused by Glu34Lys mutation. A family history was absent. Liver failure showed Budd-Chiari-like formation, including enlargement of the caudate lobe and liver congestion. Although the patient showed end-stage liver cirrhosis and renal failure, only liver transplant was performed considering the burden for a living donor. The enlarged liver (4.9 kg) showed amyloid deposition in parenchyma and the space of Disse. Amyloid also accumulated in the giant spleen. The APOA1 mutation Glu34Lys is extremely rare, and in this case hepatic failure was successfully treated by liver transplant to both replace organ function and reduce production of the amyloidogenic ApoA-1-variant protein. Careful observation for reaccumulation of amyloidosis in the organ is required.
Identifiants
pubmed: 33573822
pii: S0041-1345(21)00012-9
doi: 10.1016/j.transproceed.2020.11.012
pii:
doi:
Substances chimiques
Apolipoprotein A-I
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1327-1332Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.